Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (March 2021)
19 slides from Enveric Biosciences's investor presentation, March 2021
Slide 1: Extending & Enhancing Life for Cancer Patients
EXTENDING & ENHANCING LIFE FOR CANCER PATIENTS (NASDAQ: ENVB) MARCH 2021 WWW.ENVERIC.COM
Slide 2: Disclaimer
Disclaimer The information contained in this presentation is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions or concerns about your health, you should always consult a qualified healthcare professional. Do not disregard, avoid, or delay obtaining
Slide 3: Company Overview
Company Overview • Strong Financial Base • 18 Months of Cash on Hand Mission • No Debt Extend + Enhance the Life of • Strong Liquidity Cancer Patients who Live with • Clean Cap Table the Debilitating Side Effects of Cancer Treatment • Progress our Targeted Clinical Initiatives Vision • GBM (EV101),
Slide 4: Management Team
Management Team DAVE JOHNSON AVANI KANUBADDI DR. ROBERT WILKINS JOHN VAN BUITEN CPA CEO and Chairman Elect Chief Operating Officer Chief Medical Officer Chief Financial Officer Former CEO of Convatec, Former CEO of Welmedix, Former Medical Director at Experienced financial oversaw the $4.1B spin out
Slide 5: Our Strategy
Our Strategy Develops and/or identifies undervalued, under-researched, naturally occurring compounds; advancing these compounds in partnership with leading clinics; and plans to partner for commercial opportunities. IDENTIFY RESEARCH 01. Identify promising natural compounds that have strong anecdota
Slide 6: Key Accomplishments in 2021
Key Accomplishments in 2021 December 31, 2020: February 25, 2021: Started trading on Nasdaq Expanded our partnerships • Strong liquidity early • Exclusive agreement with January 15, 2021: PureForm Global Enhanced our balance sheet • Raising >$20.0M in capital • No debt March 10, 2021: Expanded our s
Slide 7: Supportive Care & Cannabinoid
Supportive Care & Cannabinoid WWW.ENVERIC.COM ・ NASDAQ: ENVB 7
Slide 8: Large Unmet Need in Supportive Care
Large Unmet Need in Supportive Care • Cannabinoid derivates can be leveraged across multiple delivery methods in Nausea & supportive care indications Vomiting • Large market potential Radiodermatitis • Chemotherapy often causes adverse side effects for cancer patients Pain • Developing product candi
Slide 9: Our Pipeline
Our Pipeline A robust pipeline of novel therapies across several indications, with multiple data points expected in 2021 for radiodermatitis, glioblastoma and chemotherapy-induced neuropathy. NAME DISCOVERY PRECLINICAL PHASE 1 PHASE 2 Glioblastoma Multiforme (GBM) Radiation Dermatitis (also called R
Slide 10: Radiation Dermatitis
Radiation Dermatitis “50% of patients diagnosed with cancer will receive some form of radiation therapy. Radiodermatitis is a substantial side effect that arises directly from radiation exposure during C B D A N D D E R M AT I T I S … cancer treatment, and concerns around 95% of all cancer patients
Slide 11: Chemo-Induced Neuropathy
Chemo-Induced Neuropathy ASCO Guidelines 2020: no established agents Reduced Quality of Life for the prevention of CIN Cold-induced perioral paresthesia – 95 percent Symptoms may be central or peripheral Dyspnea – 40 percent Cryotherapy, compression therapy, exercise Strongly associated with platinu
Slide 12: Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme (GBM) PREVALENCE • 22,000 Adults in the US diagnosed each year 01. • 15,000 Resulted in Death & INCIDENCE • 2 – 3/100,000 Incidence Rate • GBM Occurs in 17% of all Brain Cancers CURRENT • Surgery / Radiotherapy 02. STANDARD • Temozolomide (TMZ) • Bevacizumab OF CARE • Median
Slide 13: PureForm – Expanding Our Partnerships
PureForm – Expanding Our Partnerships Supply & Development • Launched development collaboration and exclusive supply agreement to support cannabinoid clinical programs • Aimed to treat pain and inflammation resulting from cancer treatments initially targeting supportive care indications that include
Slide 14: Diverse Biotech – Expanding Our Scientific Options
Diverse Biotech – Expanding Our Scientific Options Exclusive License for Novel Molecules • Acquired an exclusive, perpetual license from Diverse Biotech, for 5 molecules, 4 of which are dermatology-focused and one that is pain- focused • Gain access to scientists and formulators to help with the res
Slide 15: World Class Institutional Partnerships
World Class Institutional Partnerships Developed partnerships with leading global institutions for WORLD CLASS INSTITUTIONS researching, developing and commercializing its naturally and Oncologists to Partner and Advise occurring compounds. St. George’s, University of London • Research capabilities
Slide 16: Catalysts Going Forward
Catalysts Going Forward Radiation Dermatitis – Preparation: Initiate Phase I/II Trial Radiation Dermatitis – GMP IND Filing Glioblastoma Multiforme – Initiate Phase I/II Trial Formulation Glioblastoma Multiforme – Preclinical MOH Approval Va l i d at i o n Q3 Q4 2021 WWW.ENVERIC.COM ・ NASDAQ: ENVB 1
Slide 17: Industry Comps
Industry Comps NAME TA R G E T S TA G E MARKET CAP* Cara Therapeutics (NASDAQ: CARA) Chronic Pruritus Phase II Trials $965 Million Corbus Pharmaceuticals (NASDAQ: CRBP) Inflammatory and Fibrotic diseases Phase III $275 Million Zynerba (NASDAQ: ZYNE) Neuropsychiatric Conditions Phase II+ $210 Million
Slide 18: Investment Highlights
Investment Highlights We are a patient-centric biotechnology company Large Markets – Unmet Medical Strong Financial Base Strong Successful Team Needs Leadership Team – 125 Years of $20+ Million in Cash Multiple Ways to Win Success Innovative Scientific Solutions – BOD – Leveraging Skill Sets and No
Slide 19: Thank You for Your Time
THANK YOU FOR YOUR TIME David Johnson, CEO • Enveric Biosciences, Inc. • Email: djohnson@enveric.com (NASDAQ: ENVB) MARCH 2021 WWW.ENVERIC.COM
Enveric Biosciences — Investor Presentation (March 2021) on 6ix